STRATA's CEO Gambit: Can a Commercial Star Turn Code into Cash?

HORSHAM, PA – July 28, 2026 – In the high-stakes world of medical technology, a press release announcing a new CEO is rarely just about a change in leadership. It’s a signal, a strategic pivot written in corporate language. For STRATA Skin Sciences, the appointment of industry veteran Erica Jordan as its new chief executive is nothing short of a declaration of intent: the era of simply having good technology is over. The era of commercial execution has begun, and it’s a race against the clock.

STRATA finds itself in a paradoxical position. The company is a leader in excimer laser therapy, with its XTRAC® system considered a key tool for treating chronic skin conditions. It also sits on the cusp of a reimbursement gold rush, thanks to a landmark expansion of insurance codes. Yet, the company’s recent history is a narrative of financial distress. With revenues down 9% in 2025, a Nasdaq delisting in February, and a "going concern" warning hanging over its head, STRATA has the assets but has failed to cash them in. The board’s answer isn’t a new scientist or a turnaround specialist in the traditional sense. It’s a commercial powerhouse.

The Commercial Imperative: Why Erica Jordan?

Erica Jordan is not being brought in to reinvent the laser. She’s being brought in to sell it. Her 25-year career is a highlight reel of commercial scaling at giants like Philips Healthcare, Siemens, and most recently, as Chief Commercial Officer at Revance Therapeutics. She is, by definition, a growth-driver, specializing in transforming sales operations and expanding market reach.

This is precisely the skillset STRATA has been missing. The company's chairperson, Dr. Uri Geiger, was explicit in his reasoning, stating the board looks forward to Jordan translating "the historical expanded CPT Code coverage into commercial success." This isn't a subtle hint; it's the entire job description. While thanking outgoing CEO Dr. Dolev Rafaeli for his long tenure in building the company's foundation, the message is clear: the architect is leaving, and the master salesperson has arrived.

The numbers paint a stark picture of this necessity. Despite a 70% share of its 2025 revenue coming from recurring dermatology procedures—a testament to its underlying model—total revenue fell to $30.7 million. The company's accumulated deficit stands at a staggering $254.4 million. Jordan’s mandate is to reverse this trajectory by aggressively capitalizing on the tools her predecessor helped put in place. She inherits a company with proven clinical outcomes but a broken growth engine. Her job is to fix the engine, not redesign the car.

Unlocking a $1.4 Billion Market

The "historical expanded CPT Code coverage" Dr. Geiger mentioned is the single greatest opportunity in STRATA’s history. For years, the CPT codes (96920-96922) that allow dermatologists to get paid for using excimer lasers were primarily limited to treating psoriasis. This created a significant bottleneck, as the technology is effective for a much wider range of inflammatory and autoimmune skin conditions.

Effective January 1, 2027, that bottleneck will be blown wide open. The American Medical Association has revised the code descriptors to explicitly include vitiligo, atopic dermatitis, alopecia areata, and mycosis fungoides, among others. This single administrative change is poised to expand the addressable patient population from roughly 10 million psoriasis sufferers to over 30 million people. The Centers for Medicare & Medicaid Services (CMS) has already signaled its recognition, even increasing payment rates for the codes by 3.5% for 2026.

This transforms the market landscape overnight. Projections for the dermatology excimer laser market, currently valued around $112 million, now point towards a potential surge, with some analysts forecasting it to reach $1.42 billion by 2032. This isn’t just incremental growth; it’s a paradigm shift. And STRATA, with its established XTRAC® system, is perfectly positioned at the epicenter. But position means nothing without execution—the very reason for Jordan’s appointment.

The Partnership Model: STRATA's Secret Weapon?

So, how does Jordan plan to capture this expanded market? Her strategy will undoubtedly center on what she called the company's core strength: a business model that "removes the capital barrier for dermatology practices." This is STRATA’s secret weapon: the Partnership Program.

Unlike competitors who sell their devices for a large upfront sum, STRATA places its XTRAC® systems in clinics and charges a fee per treatment. This de-risks the adoption of new technology for dermatologists. A practice doesn’t need to secure a massive capital loan; it can simply start offering the treatment and share a portion of the revenue with STRATA. The model includes installation, training, maintenance, and even co-op advertising support. It’s a turnkey solution designed for rapid, scalable deployment.

As of mid-2025, 844 U.S. clinics were already on this program, but the company sees a potential market of over 2,000 more. For Jordan, a leader focused on scaling commercial organizations, this model is a force multiplier. It allows her sales team to have a fundamentally different conversation with providers—one about partnership and shared revenue, not capital expenditure. As she stated, "My focus will be on scaling the commercial organization so that more practices — and ultimately more patients... have access to them." This connects the commercial strategy directly to the consumer experience, widening access by making the business case for doctors irresistible.

A New Playbook for MedTech Growth

Jordan’s appointment is more than just a corporate reshuffling at a single Pennsylvania company. It’s a microcosm of a broader trend in the MedTech industry. For decades, value was created in the lab. A company with a breakthrough device was a guaranteed winner. Today, in a crowded and complex market, innovation in the business model and commercial strategy is just as critical as innovation in the technology itself.

The transition from Dr. Rafaeli, who built the scientific and technological foundation, to Erica Jordan, who is tasked with building the commercial superstructure, is emblematic of this shift. It reflects a maturation of the market where having a great product is merely the ticket to entry. Winning requires mastering the complex interplay of reimbursement, provider economics, and patient access.

STRATA is making a calculated bet that its future lies not in the next patent, but in its ability to execute a flawless commercial strategy ahead of the 2027 reimbursement expansion. The company has the technology, the recurring revenue model, and a massive, unlocked market opportunity. In Erica Jordan, it believes it has finally found the leader to connect the dots and turn latent potential into tangible, and desperately needed, growth.